Zenodo
What is the risk of pneumonia associated with adalimumab in a patient with COPD, moderate emphysema, and asthma?
By Tripdatabase.
Abstract
No direct evidence for the risk of pneumonia with adalimumab in COPD, emphysema, and asthma, but general data indicates an increased infection risk. Enhanced monitoring and preventive approaches are advised.
Keywords
- Chronic Obstructive Pulmonary Disease (COPD) Research
- adalimumab
- pneumonia
- chronic obstructive pulmonary disease
- emphysema
- asthma
- infection risk
- TNF-alpha inhibitors